Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dare BioscienceDARE +5.88%24 3-1 Month Momentum % is -19.84% as of Aug. 12, 2026. GuruFocus rates DARE with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 1,386 Biotechnology companies, Dare Bioscience ranks worse than 70.78% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), Dare Bioscience's 3-1 Month Momentum % is -19.84%.
The industry rank for Dare Bioscience's 3-1 Month Momentum % or its related term are showing as below:
DARE's 3-1 Month Momentum % is ranked worse than 70.78% of 1386
companies
in the Biotechnology industry
Industry Median: -7.05
vs DARE: -19.84
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Dare Bioscience 3-1 Month Momentum % Related Terms
DARE vs CLRB, NEUP, LGVN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Dare Bioscience's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (DARE) has a 3-1 Month Momentum % of -19.84% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dare Bioscience and its competitors. According to the industry distribution chart, Dare Bioscience ranks #981 out of 1386 companies in the Biotechnology industry, placing it in the top 70.8%.
Is Dare Bioscience's 3-1 Month Momentum % too high?
Dare Bioscience's current 3-1 Month Momentum % is -19.84%. Based on the distribution chart, Dare Bioscience ranks #981 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dare Bioscience has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's 3-1 Month Momentum % compare to CLRB and NEUP?
According to the Biotechnology industry distribution chart, Dare Bioscience ranks #981 out of 1386 companies for 3-1 Month Momentum %. This places Dare Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current 3-1 Month Momentum % is -19.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current 3-1 Month Momentum % of -19.84%. The current 3-1 Month Momentum % is -19.84%. Dare Bioscience's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Dare Bioscience (DARE), the current 3-1 Month Momentum % is -19.84% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
24GF Score
Get the complete analysis for DARE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DARE has been successfully added to your 
